Aktis Oncology, Inc.
AKTS
$18.75
$0.030.16%
NASDAQ
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Net Income | -25.56% | ||||
| Total Depreciation and Amortization | 57.60% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 163.70% | ||||
| Change in Net Operating Assets | -110.05% | ||||
| Cash from Operations | -19.08% | ||||
| Capital Expenditure | -86.36% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | 28.33% | ||||
| Cash from Investing | 26.85% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | 296.92% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 44.89% | ||||
| Cash from Financing | 57.21% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 24.01% | ||||